Guanidine compounds and their use as binding partners for 5-HT5 receptors

Abstract

The present invention relates to guanidine compounds of the general formula I

$$Q \xrightarrow{N} \begin{array}{c} R^3 \\ N & Z \\ N & R^1 \end{array}$$

corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.